Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • SonoThera bags $125M series B to advance safer gene therapies
  • M&A / Deals

SonoThera bags $125M series B to advance safer gene therapies

BioSpace

Instead of using viral vectors, SonoThera's genetic medicines are delivered through an ultrasound-mediated technology that could help sidestep key safety issues with conventional delivery methods.

Gene Therapy Platform

Read full story

pharminent June 11, 2026 (Last updated: June 15, 2026)

BioSpace

Instead of using viral vectors, SonoThera’s genetic medicines are delivered through an ultrasound-mediated technology that could help sidestep key safety issues with conventional delivery methods.

Gene Therapy Platform

Read full story

Post navigation

Previous: Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
Next: Novartis gets win for another Avidity muscular dystrophy AOC

Related Stories

  • M&A / Deals

BioMarin spends up to $490m for Alesta’s bone disease candidate

pharminent August 19, 2026
  • M&A / Deals

J&J hands lymphoma bispecific CAR T back to AbelZeta

pharminent August 17, 2026
  • M&A / Deals

Novo Nordisk and AWS form AI partnership to speed drug discovery

pharminent August 17, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.